Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Inovio Pharmaceuticals, Inc.

NASDAQ: INO · Life Sciences · 5 alerts · CIK 1055726

Share price
$1.40Close, Nov 16
Market cap
$262M
Shares outstanding
187.31MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Inovio Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:08 PM ET 8-K
Financial Results

Inovio Pharmaceuticals Financial Results

INOVIO reported Q3 2026 financial results and highlighted the landmark FDA accelerated approval of VOCERYQ, the first-ever approved DNA medicine, for the treatment of Recurrent Respiratory Papillomatosis (RRP). The company recently completed a public offering raising $80.5 million in net proceeds to support the commercial launch of VOCERYQ, which is expected to be available for order in early 2027.

“We are delighted with the recent approval of VOCERYQ, which FDA described as a groundbreaking therapy that fights RRP at its source, not only its symptoms. INOVIO is now a commercial stage company with a primary goal to establish VOCERYQ as the preferred first-line immunotherapy for RRP patients.”

Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer

“Our recently completed public offering provides additional financial resources to support a successful launch. Furthermore, this approval validates our DNA medicine platform and we are actively seeking partnerships to accelerate the development of other exciting candidates within our pipeline”

Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer
4:02 PM ET 10-Q
Financial Results

Inovio Pharmaceuticals Q3 2026 Results: Net Loss of $49.2M, Loss Widens

Inovio Pharmaceuticals reported a net loss of $49.2 million for the third quarter of 2026, with total assets decreasing to $60.1 million from $74.3 million at year-end 2025. The company highlighted substantial doubt about its ability to continue as a going concern, noting that current working capital is only sufficient to fund operations through the fourth quarter of 2027.

Key figure
Net loss $49.2M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.